Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page now includes an additional condition keyword 'Fallopian tube cancer' and a new resource link to the Genetic and Rare Diseases Information Center. The page revision is updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page shows a revision from v3.4.0 to v3.4.1, indicating a backend/template update. No study data, eligibility criteria, or results are altered, and To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedThe changes are minor UI/metadata updates including the addition of a glossary display and revised footer/version information (e.g., Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check84 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing the previous v3.3.3. No study data, eligibility criteria, or key content appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.